Plasma homocysteine and hematological factors in patients with venous thromboembolic diseases in Kuwait

Acta Haematologica

Volumn 117, Issue 2, 2007, Pages 98-105

  Marouf, Rajaa ^a   Mojiminiyi, Olusegun ^a   Qurtom, Mohammad ^b   Abdella, Nabila ^a   Al Wazzan, Hanan ^b   Al Humood, Salah ^a   Al Mazeedy, Madeeha ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MINISTRY OF HEALTH   (Kuwait)

Author keywords

Hematological risk factors; Homocysteine; Thrombophilia; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; CREATININE; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLIC ACID BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; KUWAIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; KUWAIT; MALE; PROTEIN C; PROTEIN S; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33847017191     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097384     Document Type: Article

References (36)

1. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM: Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877.
2. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA: Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol 2002;39:183-190.
3. Booth GL, Wang EE: Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. CMAJ 2000;163:21-29.
4. Dahlback B, Carlson M, Svenson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in the blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
6. Cumming AM, Shiach CR: The investigation and management of inherited thrombophilia. Clin Lab Haematol 1999;21:77-92.
7. Marangon K, O'Byrne D, Devaraj S, Jialal I: Validation of an immunoassay for measurement of plasma total homocysteine. Am J Clin Pathol 1999;112:757-762.
8. Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays. NCCLS Document H21-A2, No 23. Wayne, NCCLS, 1991, vol 11.
9. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE: Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study. Arch Intern Med 2000;160:961-964.
13. Chambers JC, McGregor A, Jean-Marie J, Kooner JS: Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37.
14. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
15. Rees MM, Rodgers GM: Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-359.
16. McCully KS: Chemical pathology of homocysteine. 1. Atherogenesis. Ann Clin Lab Sci 1993;23:477-493.
17. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-1914.
18. Miner SE, Evrovski J, Cole DE: Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem 1997;30:189-201.
19. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ: Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-1782.
20. den Heijer M: Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med 2003;41:1404-1407.
21. Harrington DJ, Malefora A, Schmeleva V, Kapustin S, Papayan L, Blinov M, Harrington P, Mitchell M, Savidge GF: Genetic variations observed in arterial and venous thromboembolism - relevance for therapy, risk prevention and prognosis. Clin Chem Lab Med 2003;41:496-500.
22. Kuo L, Davis MJ, Cannon MS, Chilian WM: Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res 1992;70:465-476.
23. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K, Prins MH, Buller HR, van der Meer J: The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002;116:625-631.
24. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-235.
25. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-1083.
26. Willems HPJ, Havekes M, Berenchot H: Homocysteine as a risk factor for venous thrombosis in the elderly. Neth J Med 1998;52:32S.
27. Brattstrom L, Tengborn L, Israelsson B, Hultberg B: Plasma homocysteine in venous thromboembolism. Haemostasis 1991;21:51-57.
28. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P: Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters. Thromb Res 1993;70:123-129.
29. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U: Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med 1996;334:763-768.
30. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
31. Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH: Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993;58:468-476.
32. Graham I, Meleady R: Heart attacks and homocysteine. BMJ 1996;313:1419-1420.
33. Ray JG: Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-2106.
34. Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-176.
35. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ: Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002;54:599-618.
36. Willems HP, Gerrits WB, Rosendaal FR, den Heijer M, Blom HJ, Bos GM: The VITRO trial: study design. Neth J Med 1998;52:43S.